Drug Trial Radar · NCT06833008
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
42
Actual
Start
Mar 14, 2025
Primary completion
Apr 4, 2028
Study completion Apr 4, 2028
Sponsor
- Lead sponsor
- IpsenIndustry
- Sponsor type
- Industry
- First posted
- Feb 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new study drug IPN01195 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body.
Conditions
- Advanced Solid Tumor
Interventions
IPN01195Drug
IPN01195 will be administered at assigned dose level.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Percentage of participants with dose limiting toxicity (DLT)Time frame: Part A: within 28 days of first dose.
- Part A and B: Percentage of participants experiencing treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TE SAEs).Time frame: From the first IPN01195 administration to 30 days after last dose.
- Part A and B: Percentage of participants with dose interruptions and permanent treatment discontinuationsTime frame: From the first study drug administration to 30 days after last dose.
- Part B: Objective response rate (ORR)Time frame: Part B: At end of study (up to approximately 3 years)
Locations
13 sites in 4 countries. Site status is shown where the registry gives one.
START Mid-West
Grand Rapids, Michigan
Sarah Cannon Research Institute (SCRI) - Nashville
Nashville, Tennessee
Mary Crowley Cancer Research Centers - Medical City Hospital - Dallas
Dallas, Texas
START Mountan Region
West Valley City, Utah
Virginia Cancer Specialist- Fairfax
Fairfax, Virginia
Centre Léon Bérard - Lyon
Lyon, France
Paris Saint-Louis
Paris, France
IGR-Villejuif
Villejuif, France
Istituto Nazionale dei Tumori
Milan, Italy
Istituto Nazionale Tumori IRCCS - Fondazione Pascale
Naples, Italy
Val D'Hebron
Barcelona, Spain
Hospital Universitario Quirónsalud Madrid
Madrid, Spain
M.D. Anderson Center Madrid
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.